{"disease":{"id":"type-2-diabetes-mellitus","name":"type 2 diabetes mellitus"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 18 years of age and older with chronic heart disease, chronic lung disease, diabetes mellitus, or functional or anatomical asplenia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"nateglinide","indication_name":"Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Starlix","generic_name":"NATEGLINIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Glinide [EPC]","quality_score":75,"revenue":null,"mechanism":"Starlix works by binding to the sulfonylurea receptor 1, Kir6.2, to stimulate insulin release from pancreatic beta cells."},{"drug_id":"caduet","indication_name":"Type 2 Diabetes Mellitus with multiple risk factors for CHD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"saroglitazar","indication_name":"Diabetic dyslipidemia associated with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipaglyn","generic_name":"SAROGLITAZAR","company_name":"Cadila Healthcare","drug_phase":"marketed","molecular_target":"Peroxisome proliferator-activated receptor alpha","drug_class":"","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"bromocriptine","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Parlodel","generic_name":"BROMOCRIPTINE","company_name":"Esjay Pharma","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Ergot Derivative","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"glimepiride","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amaryl","generic_name":"GLIMEPIRIDE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Sulfonylurea receptor 1, Kir6.2","drug_class":"Sulfonylurea [EPC]","quality_score":62,"revenue":null,"mechanism":"Amaryl works by binding to the sulfonylurea receptor 1 (SUR1) and Kir6.2 subunit of the ATP-sensitive potassium channel, closing the channel and depolarizing the pancreatic beta cell membrane, leading to insulin release."},{"drug_id":"rosiglitazone","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avandia","generic_name":"ROSIGLITAZONE","company_name":"Woodward","drug_phase":"marketed","molecular_target":"CDGSH iron-sulfur domain-containing protein 1","drug_class":"Peroxisome Proliferator Receptor gamma Agonist","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"metformin","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glucophage","generic_name":"metformin","company_name":"Generic (originally Merck Serono/Lipha)","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Activates AMP-activated protein kinase (AMPK) to reduce hepatic glucose production and improve insulin sensitivity without causing hypoglycemia."},{"drug_id":"ertugliflozin-15-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 15 mg","generic_name":"ertugliflozin-15-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"telmisartan","indication_name":"Disorder due to type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":80,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"glucophage","indication_name":"Treatment Refractory Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glucophage","company_name":"Dr. Reddy's Laboratories Limited","drug_phase":"marketed","molecular_target":"5'-AMP-activated protein kinase subunit beta-1, Solute carrier family 22 member 1, Solute carrier family 22 member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"benfluorex","indication_name":"Type 2 diabetes mellitus in obese","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benfluramate","generic_name":"BENFLUOREX","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"benfluorex","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"exenatide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"EXENATIDE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by mimicking the action of a natural hormone in the body to regulate blood sugar levels."},{"drug_id":"colesevelam","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Welchol","generic_name":"COLESEVELAM","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Bile Acid Sequestrant","quality_score":47,"revenue":null,"mechanism":"Welchol works by binding to bile acids in the gut, reducing their reabsorption and increasing their excretion, which in turn lowers cholesterol levels and improves blood sugar control."},{"drug_id":"repaglinide","indication_name":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prandin","generic_name":"repaglinide","company_name":"Novo Nordisk","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family C member 8","drug_class":"Glinide [EPC]","quality_score":80,"revenue":null,"mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade."},{"drug_id":"ertugliflozin-5-mg","indication_name":"Treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ertugliflozin 5 mg","generic_name":"ertugliflozin-5-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SGLT2","drug_class":"SGLT2 inhibitor","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"byetta","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Byetta","generic_name":"Byetta","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor","drug_class":"GLP-1 Receptor Agonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Byetta works by activating the glucagon-like peptide 1 receptor, which helps regulate blood sugar levels."},{"drug_id":"pramlintide","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Symlin","generic_name":"PRAMLINTIDE","company_name":"Astrazeneca Ab","drug_phase":"marketed","molecular_target":"Amylin receptor AMY2, Amylin receptor AMY1, Amylin receptor AMY3","drug_class":"","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"bydureon","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bydureon","company_name":"Phoenix VA Health Care System","drug_phase":"marketed","molecular_target":"Glucagon-like peptide 1 receptor, Glucagon-like peptide 1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pritor","indication_name":"Disorder due to type 2 diabetes mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"welchol","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Welchol","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sitagliptin-and-metformin","indication_name":"Type 2 Diabetes Mellitus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"sitagliptin and metformin","company_name":"University Medical Centre Ljubljana","drug_phase":"marketed","molecular_target":"","drug_class":"Dipeptidyl Peptidase 4 Inhibitor [EPC]","quality_score":22,"revenue":null,"mechanism":null},{"drug_id":"bromocriptin","indication_name":"Type 2 Diabetes Mellitus Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bromocriptin","company_name":"University Hospital, Bonn","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 6, Alpha-synuclein, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03811470","title":"China Diabetes Registry by Metabolic Management Center","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Guang Ning","has_results":false},{"nct_id":"NCT04927858","title":"A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017","phase":"","overall_status":"COMPLETED","enrollment_count":460558,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05004428","title":"A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)","phase":"","overall_status":"COMPLETED","enrollment_count":336376,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05073692","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","phase":"","overall_status":"COMPLETED","enrollment_count":241981,"lead_sponsor_name":"Kaiser Permanente","has_results":true},{"nct_id":"NCT06099067","title":"Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)","phase":"","overall_status":"COMPLETED","enrollment_count":239990,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07198191","title":"SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06608212","title":"An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06769646","title":"SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data","phase":"","overall_status":"COMPLETED","enrollment_count":110074,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT02713321","title":"Impact of Medicaid Health Home on Patients With Diabetes in New York City","phase":"","overall_status":"COMPLETED","enrollment_count":96759,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":true},{"nct_id":"NCT06913881","title":"Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes","phase":"","overall_status":"COMPLETED","enrollment_count":92100,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06278207","title":"An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05526157","title":"An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice","phase":"","overall_status":"COMPLETED","enrollment_count":50000,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07203677","title":"Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)","phase":"","overall_status":"COMPLETED","enrollment_count":49065,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03648424","title":"Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses","phase":"","overall_status":"COMPLETED","enrollment_count":48262,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05628090","title":"A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India","phase":"","overall_status":"COMPLETED","enrollment_count":47885,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03569735","title":"Nanshan Elderly Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01964963","title":"Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":19192,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02002975","title":"Pioglitazone Special Drug Use Surveillance \"Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus\"","phase":"","overall_status":"COMPLETED","enrollment_count":18223,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02322762","title":"DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":15992,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05703880","title":"An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":15948,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01144338","title":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14752,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT00790205","title":"Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":14671,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03847116","title":"Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease","phase":"","overall_status":"COMPLETED","enrollment_count":14014,"lead_sponsor_name":"Ningbo No. 1 Hospital","has_results":false},{"nct_id":"NCT04255433","title":"A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13299,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT07104422","title":"An Epidemiological and Long-Term Endpoint Registry Study on Disease-Syndrome Correlation Patterns in Comorbid Population With Diabetes and Ischemic Cardio-Cerebrovascular Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Guangzhou University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT03315143","title":"Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":10584,"lead_sponsor_name":"Lexicon Pharmaceuticals","has_results":true},{"nct_id":"NCT06959030","title":"An Observational Study on the Safety and Efficacy of Henagliflozin in Chinese Patients With Type 2 Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Second Affiliated Hospital of Guangxi Medical University","has_results":false},{"nct_id":"NCT03525769","title":"Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT01986881","title":"Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":8246,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02200666","title":"Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use","phase":"","overall_status":"COMPLETED","enrollment_count":7793,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07421921","title":"Detecting Type 2 Diabetes From Voice","phase":"","overall_status":"COMPLETED","enrollment_count":7319,"lead_sponsor_name":"Thymia Limited","has_results":false},{"nct_id":"NCT07106879","title":"Non-interventional Pre-screening Protocol Aims to Evaluate Participants for Potential Trial Eligibility in Future Clinical Trials/Studies Focusing on Metabolic and Psychiatric Health.","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Clindove Research LLC","has_results":false},{"nct_id":"NCT07124039","title":"An Observational Study Called FIRST-2.0 China to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions in a Chinese Population.","phase":"","overall_status":"COMPLETED","enrollment_count":6537,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT00829660","title":"Acarbose Cardiovascular Evaluation Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":6526,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT01709305","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":5570,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02290301","title":"An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin","phase":"","overall_status":"COMPLETED","enrollment_count":5180,"lead_sponsor_name":"LG Life Sciences","has_results":false},{"nct_id":"NCT05348733","title":"A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4613,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01703208","title":"A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":4202,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03496298","title":"Effect of Efpeglenatide on Cardiovascular Outcomes","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":4076,"lead_sponsor_name":"Sanofi","has_results":true},{"nct_id":"NCT06293417","title":"To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","phase":"NA","overall_status":"RECRUITING","enrollment_count":3958,"lead_sponsor_name":"Korea University Anam Hospital","has_results":false},{"nct_id":"NCT06355219","title":"Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines","phase":"","overall_status":"COMPLETED","enrollment_count":3932,"lead_sponsor_name":"Ali Aminian","has_results":false},{"nct_id":"NCT04980040","title":"A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea","phase":"","overall_status":"COMPLETED","enrollment_count":3623,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01357135","title":"An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)","phase":"","overall_status":"COMPLETED","enrollment_count":3453,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01945216","title":"Alogliptin Tablets Special Drug Use Surveillance \"Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI\"","phase":"","overall_status":"COMPLETED","enrollment_count":3317,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT01990300","title":"Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus","phase":"","overall_status":"COMPLETED","enrollment_count":3281,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT03555591","title":"Specified Drug-Use Survey of Trelagliptin Tablets \"Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus\"","phase":"","overall_status":"COMPLETED","enrollment_count":3198,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT02252224","title":"Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance","phase":"","overall_status":"COMPLETED","enrollment_count":3123,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06336239","title":"PrevaLence of Albuminuria in Patients With CARdiovascular Disease and Type 2 Diabetes Mellitus in China: a National Cross-sectional Study","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT03156985","title":"Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":3000,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}